These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 29253743)
41. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help? Mancinelli CR; Scarpazza C; Santuccio G; De Rossi N; Capra R Neurol Sci; 2018 May; 39(5):965-966. PubMed ID: 29302813 [No Abstract] [Full Text] [Related]
42. Evolution of MRI appearances due to progressive multifocal leucoencephalopathy following natalizumab treatment for multiple sclerosis. Campbell S; Kanodia AK; O'Riordan J BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25878241 [No Abstract] [Full Text] [Related]
43. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. Warnke C; Wijburg MT; Hartung HP; Killestein J; Adams O; Wattjes MP J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1092-1094. PubMed ID: 28490505 [No Abstract] [Full Text] [Related]
44. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Clerico M; Artusi CA; Di Liberto A; Rolla S; Bardina V; Barbero P; De Mercanti SF; Durelli L Expert Opin Drug Saf; 2017 Aug; 16(8):963-972. PubMed ID: 28641055 [TBL] [Abstract][Full Text] [Related]
47. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Clavel G; Moulignier A; Semerano L Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224 [TBL] [Abstract][Full Text] [Related]
48. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Oshima Y; Tanimoto T; Yuji K; Tojo A Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084 [TBL] [Abstract][Full Text] [Related]
49. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. Borchardt J; Berger JR Mult Scler Relat Disord; 2016 Jul; 8():145-50. PubMed ID: 27456891 [TBL] [Abstract][Full Text] [Related]
50. A giant MS plaque mimicking PML during natalizumab treatment. Twyman C; Berger JR J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466 [TBL] [Abstract][Full Text] [Related]
51. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort. Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121 [TBL] [Abstract][Full Text] [Related]
52. Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy. Lo Buono V; D'Aleo G; Cammaroto S; De Cola MC; Palmese F; Smorto C; Marino S; Venuti G; Sessa E; Rifici C; Corallo F Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454389 [TBL] [Abstract][Full Text] [Related]
53. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217 [TBL] [Abstract][Full Text] [Related]